HC Wainwright Raises BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target to $29.00

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its target price boosted by stock analysts at HC Wainwright from $27.00 to $29.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 193.23% from the stock’s previous close.

BBOT has been the topic of several other research reports. Raymond James Financial raised shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Stifel Nicolaus assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Weiss Ratings started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They set a “sell (d+)” rating for the company. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.00.

BridgeBio Oncology Therapeutics Price Performance

Shares of BBOT stock opened at $9.89 on Friday. BridgeBio Oncology Therapeutics has a 52-week low of $8.50 and a 52-week high of $14.87. The company has a market cap of $791.09 million, a P/E ratio of -9.60 and a beta of 0.28.

Institutional Trading of BridgeBio Oncology Therapeutics

Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC increased its holdings in shares of BridgeBio Oncology Therapeutics by 142.7% in the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after acquiring an additional 588,000 shares during the period. Laurion Capital Management LP boosted its position in BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after purchasing an additional 419,138 shares in the last quarter. Catalio Capital Management LP purchased a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at about $5,142,000. Paradigm Biocapital Advisors LP raised its holdings in BridgeBio Oncology Therapeutics by 21.2% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after purchasing an additional 395,608 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth about $1,185,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.